Glucox Biotech has been approved its third patent application in Europe in April 2010. The examining Division has granted the European patent that will cover the use of NAD(P)H oxidase inhibitors as a medicament in the treatment and/or prevention of diseases caused by diabetes.

The patent received will provide a strong commercial protection for pharmaceutical products proceeding within the company and adds extended value to the existing IP-portfolio of Glucox Biotech.

Glucox Biotech is currently testing its novel compounds in animal tests and is preparing for a clinically applicable therapeutic drug for treatment of type 2 diabetes and insulin resistance as well as diabetes complications.